Journals / Solunum / 2013 / Cilt: 15 - Sayı: 1

Comparison of Serum Levels for VEGF and Markers of Inflammation in COPD and Their Relationship with Functional Parameters

Kronik Obstrüktif Akciğer Hastalığında Vasküler Endotelyal Growth Faktör ile İnflamasyon Belirteçlerinin Kan Düzeylerinin Karşılaştırılması ve Fonksiyonel Parametrelerle Arasındaki İlişki

Journal
Solunum
Pages
25–31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The positive correlation between VEGF and PaCO2 levels in COPD patients suggests that VEGF may be released by another potential stimulant in response to hypoxemia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of the present study was to determine circulating levels of vascular endothelial growth factor (VEGF) and markers of systemic inflammation in patients with stable and exacerbated chronic obstructive pulmonary disease (COPD) and to assess the relationship between markers of systemic inflammation, hypoxemia, hypercapnia and lung function parameters with circulating VEGF levels in both stable and exacerbated COPD.
📊
Key Findings & Data:Materials and Methods: Lung function parameters, arterial blood gas analysis and circulating levels of VEGF, interleukin-6, C-reactive protein, fibrinogen and peripheral blood neutrophil cell counts were assessed in 30 patients upon admission to the hospital for an acute exacerbation of COPD, in 30 patients with stable COPD, and in 30 controls with normal lung function.
💡
Conclusion & Impact:The positive correlation between VEGF and PaCO2 levels in COPD patients suggests that VEGF may be released by another potential stimulant in response to hypoxemia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The aim of the present study was to determine circulating levels of vascular endothelial growth factor (VEGF) and markers of systemic inflammation in patients with stable and exacerbated chronic obstructive pulmonary disease (COPD) and to assess the relationship between markers of systemic inflammation, hypoxemia, hypercapnia and lung function parameters with circulating VEGF levels in both stable and exacerbated COPD. Materials and Methods: Lung function parameters, arterial blood gas analysis and circulating levels of VEGF, interleukin-6, C-reactive protein, fibrinogen and peripheral blood neutrophil cell counts were assessed in 30 patients upon admission to the hospital for an acute exacerbation of COPD, in 30 patients with stable COPD, and in 30 controls with normal lung function. In patients with acute exacerbations of COPD, circulating cytokine concentrations and other laboratory markers were reassessed six weeks later. Results: Fibrinogen levels in exacerbated COPD patients were higher than in stable COPD and healthy controls (398.8±97.6, 310.3±11.3, 236.1±94.3, respectively). Although IL-6 levels in COPD patients were significantly higher than in the control group, there was no significant difference between stable and exacerbated COPD. VEGF levels in exacerbated COPD patients were higher than in stable COPD and controls, but the difference was not statistically significant. There was no correlation between VEGF levels and inflammation markers, functional parameters or PaO2 , but there was a positive correlation between PaCO2 and VEGF in COPD patients. Conclusion: Our study revealed that fibrinogen is a systemic inflammatory marker that reflects exacerbations of COPD and it is correlated with disease severity. We conclude that IL-6 levels are valuable for showing the presence of systemic inflammation in COPD. The positive correlation between VEGF and PaCO2 levels in COPD patients suggests that VEGF may be released by another potential stimulant in response to hypoxemia.

Özet

Amaç: Çalışmamızın amacı KOAH'ın stabil ve alevlenme döneminde sistemik enflamasyon belirteçlerinin ve vasküler endotelyal growth faktörün (VEGF) kan düzeylerini saptamak ve sistemik inflamasyon belirteçleri, hipoksemi, hiperkarbi ve akciğer fonksiyon testleri ile kan VEGF düzeyleri arasındaki ilişkiyi araştırmaktı.Gereç ve Yöntem: Çalışmamıza KOAH alevlenme nedeni ile hastaneye müracaat eden 30 KOAH hastası, 30 stabil KOAH hastası ve 30 sağlıklı kontrol alındı.Tüm çalışma hastalarının akciğer fonksiyon parametreleri, arter kan gazı analizleri ve kanda vasküler growth faktör (VEGF), interlökin-6, C-reaktif protein, fibrinojen seviyeleri, periferik kan nötrofil sayıları bakıldı. Akut alevlenmesi olan hastalarda kandaki sitokin seviyeleri ve diğer laboratuar testleri altı hafta sonra yeniden ölçüldü.Bulgular: KOAH atak grubunda fibrinojen düzeyleri, stabil KOAH ve kontrol grubu hastalarına göre yüksek saptandı (sırasıyla 398.8±97.6, 310.3±11.3, 236.1±94.3). KOAH hasta grubu IL-6 düzeyleri, kontrol grubuna göre anlamlı derecede yüksek olmasına karşın KOAH atak ve stabil hasta grubu arasında IL-6 düzeyleri açısından anlamlı fark bulunmadı. VEGF düzeyleri ise; KOAH atak hasta grubunda, stabil KOAH ve kontrol grubuna göre yüksek saptandı. Fakat bu yükseklik istatistiksel olarak anlamlı değildi. KOAH hasta grubunda, VEGF değerleri ile inflamatuar ve fonksiyonel parametrelerle ve arter kan gazı PO2 değerleri arasında bir korelasyon saptanmaz iken, PCO2 değerleri arasında anlamlı (+) pozitif korelasyon saptandı. Sonuç: Çalışmamızda, fibrinojenin KOAH' ta atağı gösteren sistemik inflamatuar bir belirteç olduğu ve hastalığın şiddeti arttıkça inflamasyon düzeyleriyle korele fibrinojen düzeylerinin arttığı gösterildi. Tüm KOAH hastalarında IL-6 düzeylerinin kontrol grubuna göre yüksek saptanması, IL-6'nın KOAH'ta sistemik inflamasyonun varlığını göstermesi açısından anlamlı bulundu. KOAH hasta grubunda saptanan VEGF değerleri ile arter kan gazı PCO2 değerleri arasındaki (+) korelasyon, VEGF salınımı için hipoksemiden farklı potansiyel uyarıların söz konusu olabileceğini düşündürdü

🔖

Cite This Article

GÖK, N. Y., ORTAKÖYLÜ, M. G., BAHADIR, A., ALKAN, F., ÇAĞLAR, E. (2013). Comparison of Serum Levels for VEGF and Markers of Inflammation in COPD and Their Relationship with Functional Parameters. Solunum, Cilt: 15 - Sayı: 1, 25–31. https://ajindex.com/articles/314399

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Global Initative for Chronic Obstructive Lung Disease. Management of COPD. Global Strategy for the Diagnosis, Management and Pevention of Chronic Obstructive Pulmonary Disease 2006: 32-84. 2 Barnes PJ, Saphiro SD, Pauwels RA. Chronic obstructive pulmonary disease:molecular and cellular mechanisms. Eur Respir J 2003
  2. [CrossRef] 3. Yazır Y. Vasküler Endotel Büyüme Faktörü (vegf): Reseptörleri ve Fonksiyonları. C.Ü. Tıp Fakültesi Dergisi 2007
  3. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997
  4. Kanazawa H, Asai K, Hirata K, Yoshikawa J. Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med 2003
  5. [CrossRef] 6. Valipour A, Schreder M, Wolzt M, Saliba S, Kapiotis S, Eickhoff P, et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond) 2008
  6. [CrossRef] 7. Kierszniewska-Stepien D, Pietras T, Górski P, Stepien H. Serum vascular endothelial growth factor and its receptor level in patients with chronic obstructive pulmonary disease. Eur Cytokine Netw 2006
  7. Cheng SL, Wang HC, Yu CJ, Yang PC. Increased expression of placenta growth factor in COPD. Thorax 2008
  8. [CrossRef] 9. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. http://www.goldcopd.org/. 10. Anthonisen NR, Manfreda J, Warren W, Hershfıeld ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987
  9. [CrossRef] 11. Kirdar S, Serter M, Ceylan E, Sener AG, Kavak T, Karadag F. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scand J Clin Lab Invest 2009
  10. [CrossRef] 12. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001
  11. [CrossRef] 13. Mittermayer F, Pleiner J, Schaller G, Weltermann A, Kapiotis S, Jilma B, et al. Marked increase in vascular endothelial gro